Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer
Investigational New Drugs · 2024
DOI: 10.1007/s10637-024-01465-9 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Investigational New Drugs, 2024. Verfasst von Shubham Pant und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sitravatinib (MGCD516) is an oral inhibitor of several closely related oncogenic tyrosine kinase receptors that include VEGFR-2 (vascular endothelial growth factor receptor-2), AXL, and MET (mesenchymal-epithelial transition). The safety and antitumor activity of sitravatinib are reported in patients from two histologic cohorts (anti-angiogenesis-refractory clear cell renal cell carcinoma [RCC] and castrate-resistant prostate cancer [CRPC] with bone metastases) who participated in a Phase 1/1b study. The patients were enrolled using a 3-stage design that was based on observed objective responses. Objective response rate (ORR) was the primary endpoint. Duration of response, progression-free survival (PFS), overall survival (OS), and safety were also assessed. Overall, 48 patients (RCC n = 38, CRPC n = 10) received ≥ 1 dose of sitravatinib. Both cohorts were heavily pretreated (median number of prior systemic therapies: RCC cohort 3, CRPC cohort 6). In the RCC cohort, ORR was 25.9%, P = 0.015 (null hypothesis [ORR ≤ 10%] was rejected). Responses were durable (median duration 13.2 months). Median PFS was 9.5 months and median OS was 30.0 months. No objective responses were seen in the CRPC cohort; median PFS and OS were 5.8 months and 10.1 months, respectively. Across both cohorts, diarrhea (72.9%), fatigue (54.2%), and hypertension (52.1%) were the most frequent all-cause treatment-emergent adverse events (TEAEs). Diarrhea and vomiting (both, 6.3%) were the most frequent serious TEAEs considered related to study treatment. Sitravatinib demonstrated an acceptable safety profile and promising clinical activity in patients with clear cell RCC refractory to prior angiogenesis inhibitor therapy. Strong indicators for clinical activity were not seen in patients with CRPC and bone metastases. Clinical trial registration :ClinicalTrials.gov NCT02219711.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
- University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
- Virginia Cancer Specialists, Fairfax, VA, USA.
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
- Mirati Therapeutics Inc., San Diego, CA, USA.
ORCID-Profile: Sanjay Goel
Zitieren
APA
Pant, S., Cho, B. C., Kyriakopoulos, C. E., Spira, A., Tannir, N., Werner, T. L., Yan, X., Neuteboom, S., Chao, R., & Goel, S. (2024). Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01465-9
Vancouver
Pant S, Cho BC, Kyriakopoulos CE, Spira A, Tannir N, Werner TL, et al. Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01465-9
BibTeX
@article{Pant2024,
author = {Pant, Shubham and Cho, Byoung Chul and Kyriakopoulos, Christos E and Spira, Alexander and Tannir, Nizar and Werner, Theresa L and Yan, Xiaohong and Neuteboom, Saskia and Chao, Richard and Goel, Sanjay},
title = {Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer},
journal = {Investigational New Drugs},
year = {2024},
doi = {10.1007/s10637-024-01465-9}
}
EUVIMED